Lymphoma Research

Lymphoma Research

Research into lymphoma at Penn State Cancer Institute is conducted by the leukemia and lymphoma team. See current clinical trials and members of that team here.

Clinical Trials

Blood and Bone Marrow Sampling for Tissue Banking
Umbrella Long-term Follow-up Protocol
MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults With Relapsed/Refractory (R/R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants With a Suboptimal Response (CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation)
The Collection of Blood, Tissue and Phenotypic Data in Patients Diagnosed with Skin Cancers and Subsequent Metastases for Inclusion in a Repository and Use in Outcome Studies
Determinants of Survival in Allogenic Marrow and Stem Cell Transplant at Hershey Medical Center (HMC)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)
A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation

Disease Team Members

First Name Last Name Title Role
David Claxton, MD David Claxton MD View Profile
W. Christopher Ehmann, MD W. Christopher Ehmann MD View Profile
Raymond Hohl, MD, PhD Raymond Hohl MD, PhD View Profile
Muhammad Khawaja, MD Muhammad Khawaja MD View Profile
Heath Mackley, MD, FACRO Heath Mackley MD, FACRO View Profile
Shin Mineishi, MD Shin Mineishi MD View Profile
Seema Naik, MD Seema Naik MD View Profile
Witold Rybka, MD, FRCPC Witold Rybka MD, FRCPC View Profile
Henry Wagner Jr., MD Henry Wagner Jr. MD View Profile
Hong Zheng, MD, PhD Hong Zheng MD, PhD View Profile
Research into lymphoma at Penn State Cancer Institute is conducted by the leukemia and lymphoma team. See current clinical trials and members of that team here.
Blood and Bone Marrow Sampling for Tissue Banking
Umbrella Long-term Follow-up Protocol
MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults With Relapsed/Refractory (R/R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants With a Suboptimal Response (CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation)
The Collection of Blood, Tissue and Phenotypic Data in Patients Diagnosed with Skin Cancers and Subsequent Metastases for Inclusion in a Repository and Use in Outcome Studies
Determinants of Survival in Allogenic Marrow and Stem Cell Transplant at Hershey Medical Center (HMC)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)
A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)
A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation
First Name Last Name Title Role
David Claxton, MD David Claxton MD View Profile
W. Christopher Ehmann, MD W. Christopher Ehmann MD View Profile
Raymond Hohl, MD, PhD Raymond Hohl MD, PhD View Profile
Muhammad Khawaja, MD Muhammad Khawaja MD View Profile
Heath Mackley, MD, FACRO Heath Mackley MD, FACRO View Profile
Shin Mineishi, MD Shin Mineishi MD View Profile
Seema Naik, MD Seema Naik MD View Profile
Witold Rybka, MD, FRCPC Witold Rybka MD, FRCPC View Profile
Henry Wagner Jr., MD Henry Wagner Jr. MD View Profile
Hong Zheng, MD, PhD Hong Zheng MD, PhD View Profile

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)